Gilead Sciences Inc. said an unauthorized network of drug distributors and suppliers sold pharmacies more than $250 million of counterfeit versions of the company’s HIV treatments over the last two years, endangering patients.

Endo International agreed to pay up to $65 million to resolve claims by the state of Florida and local governments that the drugmaker helped fuel the U.S. opioid epidemic.

A U.S. federal judge in Texas denied attempts by the U.S. Food and Drug Administration to conceal data on Pfizer’s COVID-19 vaccine.

The state of Georgia decided to join a proposed $26 billion nationwide settlement resolving lawsuits alleging that three large drug distributors and drugmaker Johnson & Johnson fueled the deadly U.S. opioid epidemic.

Nevada agreed to back a proposed nationwide settlement worth up to $26 billion resolving lawsuits against three large drug distributors and the drugmaker Johnson & Johnson over the deadly U.S. opioid epidemic, the state’s attorney general said on January 4.

Specialty pharmaceutical company Collegium Pharmaceutical reached a $2.75 million agreement with the U.S. government to settle 27 pending lawsuits related to the opioid crisis and the company’s sale of Xtampza.

Bayer AG won a trial over claims the company’s Roundup weedkiller causes cancer after a California jury found that the herbicide was not a substantial cause of a child’s rare form of non-Hodgkin’s lymphoma. The verdict is the fourth involving Roundup and the first in the German drugmaker’s favor.

Although the U.S. Bankruptcy Court approved the OxyContin maker’s reorganization plan that freed the Sacklers from greater financial accountability and shielded them from additional lawsuits, the Department of Justice moved to block the Purdue Pharma bankruptcy deal.

An alleged plan by Johnson & Johnson to spin off a company solely responsible for J&J’s talc-based products in order to mitigate lawsuit damages is still on the table following a ruling by a federal judge.

U.S. states are racing to meet a deadline to commit to a $26 billion opioid settlement with three drug distributors and the drugmaker Johnson & Johnson, as some grapple with local resistance and concerns the amount is not large enough to address the damage done by an epidemic of addiction.